Neoplasms by Histologic Type Clinical Trials

55 clinical trials for Neoplasms by Histologic Type across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors — RECRUITING · PHASE1
• A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma — RECRUITING · PHASE1
• Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition — RECRUITING · PHASE2
• DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations — RECRUITING · PHASE2
• DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers — RECRUITING · PHASE2
• DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. — RECRUITING · PHASE2
• Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma — RECRUITING · PHASE1
• A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study — RECRUITING · PHASE1
• Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture — RECRUITING · PHASE4
• Spanish Series of Patients Treated With the Radionuclide Lutetium177 — RECRUITING
• Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients — RECRUITING · PHASE2
• Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance — NOT_YET_RECRUITING · PHASE2
• Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) — ACTIVE_NOT_RECRUITING · PHASE2
• Vorasidenib Expanded Access Program — OTHER
• Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL — ACTIVE_NOT_RECRUITING · PHASE1
• Administration of T Lymphocytes for Prevention of Relapse of Lymphomas — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies — COMPLETED · PHASE1
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) — TERMINATED · PHASE3
• DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. — NOT_YET_RECRUITING · PHASE2
• Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma — ACTIVE_NOT_RECRUITING · NA
• Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors — COMPLETED · PHASE1
• A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) — COMPLETED · PHASE2
• P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) — TERMINATED · PHASE1
• (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations — TERMINATED · PHASE1
• (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC — TERMINATED · PHASE1
• Natural Killer Cell (CYNK-001) Infusions in Adults with AML — TERMINATED · PHASE1
• Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) — TERMINATED · PHASE1
• Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors — OTHER · PHASE1
• (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC — TERMINATED · PHASE1
• Intended Use Study of the BD SurePath Plus™ Pap — TERMINATED
• A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide — TERMINATED · PHASE3
• Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma — OTHER · PHASE1
• Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus — COMPLETED
• Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors — COMPLETED · PHASE1
• A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment — OTHER · PHASE2
• A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor — OTHER · PHASE2
• Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL — OTHER · PHASE2
• Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors — COMPLETED · PHASE1
• Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma — OTHER · PHASE1
• External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC — OTHER
• Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies — SUSPENDED · PHASE1
• Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer — OTHER · PHASE2
• Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer — OTHER · PHASE2
• A Trial In Patients With Advanced Cancer And Leukemia — COMPLETED · PHASE1
• Low Rectal Cancer Study (MERCURY II) — OTHER
• Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks — OTHER · PHASE2
• Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial — OTHER
• A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma — TERMINATED · PHASE1

Refine this search